Blueprint Medicines Corporation (LON:0HOJ)
129.35
-0.04 (-0.03%)
Inactive · Last trade price on Jul 17, 2025
Blueprint Medicines Employees
Blueprint Medicines had 649 employees as of December 31, 2024. The number of employees decreased by 6 or -0.92% compared to the previous year.
Employees
649
Change (1Y)
-6
Growth (1Y)
-0.92%
Revenue / Employee
635.15K GBP
Profits / Employee
-175.96K GBP
Market Cap
6.21B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 649 | -6 | -0.92% |
| Dec 31, 2023 | 655 | 14 | 2.18% |
| Dec 31, 2022 | 641 | 146 | 29.49% |
| Dec 31, 2021 | 495 | 66 | 15.38% |
| Dec 31, 2020 | 429 | 46 | 12.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Blueprint Medicines News
- 15 days ago - Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - Benzinga
- 7 weeks ago - Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction - Business Wire
- 2 months ago - Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction - Business Wire
- 4 months ago - $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC) - GlobeNewsWire
- 4 months ago - What's Driving the Market Sentiment Around Blueprint Medicines? - Benzinga
- 5 months ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 5 months ago - Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
- 5 months ago - HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC) - Benzinga